Bionote's Vcheck T4 kit was recently validated for its outstanding performance, with results published in the Journal of Feline Medicine and Surgery, a leading international journal in feline clinical research, this past January.  The study, titled "Evaluation of a point-of-care test for quantitative determination of total thyroxine in feline serum," was conducted to verify the performance of the Vcheck T4 assay for feline thyroid function testing.  Hyperthyroidism is a common endocrine disorder in adult and senior cats. Early detection and treatment are crucial, yet diagnosis is often delayed due to its nonspecific clinical signs. In such cases, total thyroxine (TT4) evaluation serves as the most widely used primary diagnostic tool.  In this study, the Vcheck T4 demonstrated excellent reproducibility with a coefficient of variation (CV) ranging from 3.7% to 11.0%, showing performance comparable to the reference enzyme immunoassay (EIA) method.  Furthermore, as a diagnostic tool for feline hyperthyroidism, the Vcheck T4 assay showed a sensitivity of 88.9% and a specificity of 84.4%, indicating its clinical utility in evaluating thyroid function in cats.  The research team stated, "The Vcheck T4 assay provides precise and reproducible TT4 concentration results," adding that it is "a valuable tool for routine screening and ruling out hyperthyroidism in adult and senior cats."Click here for the full paper

We, BIONOTE, Inc. duly organized under the law of the Republic of Korea and having its principal place at 22 Samsung 1-ro 4-gil, Hwaseong-si, Gyeonggi-do, 18449, Republic of Korea, hereby declare that our company logo will change, effective as of 1st November 2024.We appreciate your continued support and interest in BIONOTE with our expanding vision and mission for the future business. For any further questions, please contact our Marketing Department.

                                                                                                                                      ▶High Reliability of Vcheck cPL 2.0 Test in Diagnosing and Monitoring Canine Pancreatitis has been published in the SCI-level international journal. Pancreatitis is a common condition in dogs associated with exocrine pancreatic dysfunction. Accurate diagnosis requires consideration of clinical history, symptoms, abdominal ultrasound, and laboratory tests. However, diagnosing pancreatitis can be challenging due to non-specific symptoms such as loss of appetite, lethargy, and vomiting. Traditional tests like CBC, biochemical tests, and ultrasound have low diagnostic specificity. A recent paper on Vcheck cPL 2.0 was published in the "Journal of Veterinary Science", an SCI journal.The study found that Vcheck cPL 2.0 closely matches the gold standard test, with near-perfect agreement (r = 0.958, p < 0.001). It also showed that the changes in serum cPL concentrations measured by both tests were highly consistent over time.※ For product-related inquiries, please contact the official distributors, Bionote Inc., 

                                                                                                                                                                                        For more information about the products, please visit the following page: Vcheck D-dimer 5Tests/Kit Bionote announced the release of its new D-dimer kit packaging in a 5-test format for its Vcheck immunodiagnostic equipment used in veterinary clinics.D-dimer is one of the degradation products formed when fibrin clots dissolve during the blood coagulation process. It serves as an indicator of the ongoing process of blood clotting and subsequent recovery in the body following tissue or vascular damage.This marker can be utilized as a valuable diagnostic tool for various diseases such as tumors, sepsis, pancreatitis, and immune-mediated diseases.Particularly, D-dimer testing, when used alongside other coagulation tests such as platelet count, PT (Prothrombin Time), and APTT (Activated Partial Thromboplastin Time), can significantly aid in the diagnosis of thrombosis and Disseminated Intravascular Coagulation (DIC). A representative from Bionote stated, "Compared to the existing 10-test kits, the 5-test format is advantageous for small clinics or environments with fewer emergency cases, making it more accessible. We anticipate that this will facilitate broader use of D-dimer products in veterinary hospitals, expanding the scope of coagulation testing." For product-related inquiries, please contact Bionote's official distributors, BioLine Co., Ltd., or Prochal Korea Co., Ltd.

  The outstanding performance of Vcheck M Canine Vector 8 panel (BIONOTE) and the necessity of testing for eight pathogens simultaneously have been published in two international journals, "Journal of Veterinary Research" and the "Polish Journal of Veterinary Sciences" (Science Citation Index Expanded)    Paper: J Vet Res 68, 2024 & Polish Journal of Veterinary Sciences Vol. 27, No. 2 (2024), 165–   See the attached documents for the summary and click here for the full paper of J Vet Res 68, 2024 and Polish Journal of Veterinary Sciences Vol. 27, No. 2 (2024), 165– (open access).   Two studies focused on monitoring vector-borne diseases in anemic dogs arriving in or returning to Poland from endemic regions, comparing results obtained using Vcheck M Canine Vector 8 (CV8) with those from real-time or conventional PCR.   According to the first study, molecular tests identified vector-borne pathogens in 79 dogs. All positive results from Vcheck M CV8 were validated by standard real-time PCR with no false positives detected. Therefore, the Vcheck M CV8 provides comparable results to real-time PCR. Its capability for onsite testing is crucial for promptly detecting infections and initiating timely therapy, thereby reducing the time needed for laboratory confirmation.  The second study aimed to detect Hepatozoon canis from dogs suspected of tick-borne diseases, shedding light on prevalence and clinical implications in Poland. Despite sporadic H. canis cases and infrequent R. sanguineus ticks, the study highlighted the necessity of considering H. canis in diagnosing vector-borne diseases, especially in anemic dogs in Poland. The study underscored the importance of comprehensive screening, such as with Vcheck M CV8, in identifying diverse threats, particularly amid increased travel and climate change which may introduce novel pathogens.   The Vcheck M CV8 Panel is point-of-care(POC) molecular diagnostic cartridge designed for simultaneous detection of Canine Vector-borne Disease 8 pathogens: Leishmania spp., Babesia spp., Mycoplasma haemocanis, Hepatozoon spp., Ehrlichia spp., Anaplasma spp., Rickettsia rickettsii, and Bartonella spp. in canine whole blood. Learn more

For more information about the products, please visit the following page:*Vcheck M Canine Diarrhea 8 Panel*Vcheck M Feline Diarrhea 8 PanelBionote, a global-leading company in biocontents and animal diagnostics, announced that 'Vcheck M Canine Diarrhea 8 Panel/Feline Diarrhea 8 Panel', a diagnostic cartridge product for 8 diarrhea-causing diseases in dogs and cats has received a certificate of free sales.  Vcheck M10 is an automatic analyzer that can perform both nucleic acid extraction and PCR, which previously needed to be performed separately using two different machines. The test procedure is simple enough for any veterinarian to perform on-site at the animal hospitals without separate prior training.PCR tests, normally performed by a laboratory, take about 1 to 3 days. It can be performed quickly and accurately on-site for around an hour through the cartridges, and M10 analyzer which can also be expanded to 8 channels. Customers can optimize use according to size, from labs to small and large hospitals. A BIONOTE Spokesperson commented, “The global veterinary molecular diagnostic market size is currently approximately 3 billion dollars and is expected to grow at an average annual rate of about 10% in the future. PCR testing using POCT molecular diagnostic equipment for animals is also expected to further expand.” “By obtaining this certificate of free sales, we will accelerate our effort to expand overseas markets,” he said. Meanwhile, BIONOTE recently launched the Feline Immunodeficiency Virus (FIV)/ Feline Leukemia Virus (FeLV) test cartridge and continuously exported it overseas in earnest. BIONOTE is currently developing various test panels such as respiratory, anemia-causing pathogens and panels for livestock animals.  

  ▶The global company Bionote, specializing in bio-content and animal diagnostics, announced on the 13th of May that its product, the 'Rapid CHW Ag 2.0' antigen diagnostic kit for canine heartworm, has obtained approval for sale from the United States Department of Agriculture (USDA).   Consequently, the product can be sold and distributed within the United States through Bionote's U.S. subsidiary, Bionote USA. Canine heartworm disease, transmitted primarily by mosquitoes, is a representative parasitic infectious disease in dogs. Heartworms, which primarily parasitize the pulmonary arteries, can lead to severe cardiovascular diseases and, in severe cases, death. It takes 6 to 7 months for the microfilariae transmitted by mosquitoes to grow into adult worms inside the dog's body. Clinical symptoms often do not immediately appear, which can lead to delayed diagnosis. Therefore, the American Heartworm Society (AHS) recommends monthly heartworm prevention and testing for heartworm infection at least once a year. Bionote's Canine Heartworm Antigen diagnostic kit can detect even a very small number of female worms (1 to 5 worms) and provides test results within 10 minutes. The newly approved 'Rapid CHW Ag 2.0' product is an upgraded version with a more compact design, making it even more suitable for on-site testing compared to the previously sold 'Rapid CHW Ag 1.0'. A Bionote representative stated, "According to research conducted at the University of Florida, the product has demonstrated a sensitivity and specificity of over 100% compared to the gold standard test, proving its high accuracy." They further stated, "The United States is a large market that accounts for over 40% of the global animal diagnostic testing market. We will continue to expand our presence in the U.S. market through further USDA product registrations, maximizing the sales force of our U.S. subsidiary, and collaborating with partners.

    ▶Planning to maximize the market share in on-site POC molecular diagnostics by expanding the product portfolio.BIONOTE announced on the 5th of March that they have launched ‘Vcheck M FIV/FeLV’ which is for diagnosing Feline Immunodeficiency Virus (FIV) / Feline Leukemia Virus (FeLV). M10 is an automatic analyzer that can perform both nucleic acid extraction and PCR, which previously needed to be performed separately using two different machines. The test procedure is simple enough for any veterinarian to perform on-site at the animal hospitals without separate prior training. Furthermore, depending on the user's needs, they can customize how many modules they would like to use, up to a maximum of 8, making the M10 suitable for small hospitals, large hospitals, and even labs. A BIONOTE Spokesperson commented, “Following the launch of Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) cartridge, we will now be actively expanding the export internationally starting this month.” And that “We will accelerate the sales activity with 'Canine Vector 8 panel' and 'Canine Anemia 8 panel’ and strengthen our portfolio with the POC molecular diagnostic products, including 'Diarrhea 8 panel', which will be released this year. Our goal is to maximize our global market share in the veterinary field of molecular diagnostics as well”. Meanwhile, BIONOTE also aims to domestically launch a diagnostic cartridge with Babesia gibsoni which is known as causing a fatal tick-borne disease in dogs. BIONOTE is currently developing various test panels such as respiratory, anemia-causing pathogens and panels for livestock animals.

▶ BIONOTE promoted its products and provided lectures by prominent veterinarians about their experiences of applying Vcheck F to clinical settings ▶ Strengthen veterinary network across all areas of the U.S. to expand market share    Global leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc. announced on the 19th of January that its US Branch, BIONOTE USA, participated in VMX (Veterinary Meeting & EXPO), one of the largest veterinary conferences in the world held in Orlando, Florida between the 13th and 17th of January (local time). ​The VMX Conference is held in Orlando, Florida every year with over 15,000 members of the veterinary industry such as veterinarians, veterinary students, and veterinary technicians attending for various exchanges. Further, prominent speakers give lectures and companies unveil new products and technologies for animal clinics at the event.*Veterinary technicians: helps veterinarians in diagnosing patients effectively and performs surgery preparations, surgical assistance, and postoperative recovery observations. BIONOTE focused on promoting their point of care fluorescent immunoassay analyzer 'Vcheck F V200', which is the number 1 product globally in terms of market share, along with cardiac disease-related biomarker test reagents such as 'NT-proBNP', 'TnI' and hormone biomarker test reagents such as 'Cortisol'. BIONOTE's booth also featured lectures by prominent veterinarians (Dr. Elizabeth Rozanski, Tufts Cummings School of Veterinary Medicine / Dr. Luis Tarrido, Eden Veterinary Clinic / Dr. Geri Lake-Bakaar, Evolution Veterinary Specialists) on the subject of their experience of applying Vcheck F products in clinical settings and their experience of evaluating the products. A BIONOTE spokesperson stated "To increase awareness and market share in the U.S., we are actively participating in conferences to meet and promote to veterinarians in person, with the support of KOTRA's global support project for mid-sized companies" and that "We will continue to participate in various academic conferences and exhibitions across the United States to increase brand awareness". Meanwhile, BIONOTE successfully launched three types of Equine-related biomarker products (Foal IgG, Progesterone, SAA) last year to target the U.S. market, and plans to lead the Equine diagnostic reagent market by developing additional Equine products this year. 

▶ D-dimer diagnostic kit for quantitative results in-house The sensitivity of BIONOTE's D-dimer kit, which can be used with the immunoassay analyzer Vcheck (V200 and V2400), has increased even more.  During the secondary hemostasis of the blood clotting process, fibrin clots are produced, and they are degraded by plasmids into fibrin degradation products (FDP). D-dimer is one of the final degradation products of these processes and is considered a highly sensitive biomarker for coagulation activity.The biomarker can be used to detect excessive thrombus formation early, which can aid in screening for diseases related to thrombus, such as thromboembolism (TE) or disseminated intravascular coagulation (DIC).D-dimer can be clinically utilized by testing patients with risk factors that may cause thromboembolism such as cancer, sepsis, pancreatitis, vascular disease, or immune-mediated diseases. Furthermore, it can also be utilized for preemptively preventing emergencies after surgery or to monitor the progress and effectiveness of antithrombotic therapy. A high correlation (R²=0.9289) was confirmed for the Vcheck measurements, in comparison with third-party analyzers with proven validity in canine D-dimer measurements, proving the Vcheck result's validity. A BIONOTE spokesperson stated, "The ability to screen for thrombus was improved by upgrading the performance (sensitivity) of the Vcheck D-dimer kit, which was first launched 5 years ago".The Vcheck analyzer can measure a total of 30 biomarkers including inflammation markers (CRP, SAA), pancreatitis markers (cPL, fPL), cardiac disease markers (NT-proBNP, Troponin I), kidney disease markers (SDMA), hormones (T4, TSH, Cortisol), antibody titer tests, as well as D-dimer.